Evolus, Inc. (EOLS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Core Viewpoint - Evolus, Inc. (EOLS) is expected to report a significant year-over-year increase in earnings and revenues for the quarter ended December 2025, with earnings per share (EPS) estimated at $0.06, reflecting a 500% increase, and revenues projected at $89.42 million, up 13.3% from the previous year [1][3]. Earnings Expectations - The upcoming earnings report is anticipated to be released on March 3, and the stock price may rise if the actual results exceed expectations, while a miss could lead to a decline [2]. - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. Earnings Surprise Prediction - The Most Accurate Estimate for Evolus is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +8.33%, suggesting a bullish outlook from analysts [12]. - However, the stock holds a Zacks Rank of 4, complicating the prediction of an earnings beat [12]. Historical Performance - In the last reported quarter, Evolus was expected to post a loss of $0.19 per share but delivered a smaller loss of -$0.14, resulting in a positive surprise of +26.32% [13]. - Over the past four quarters, Evolus has only beaten consensus EPS estimates once [14]. Industry Context - Perrigo (PRGO), a peer in the Zacks Medical - Products industry, is expected to report an EPS of $0.8 for the same quarter, indicating a year-over-year decline of 14%, with revenues projected at $1.1 billion, down 3.2% from the previous year [18].